title: A new therapeutic approach to treat psoriasis by inhibition of fatty acid oxidation by Etomoxir.
abstract: BACKGROUND
  The dogma in psoriasis is that due to pathogen-induced inflammatory responses, an autoreactive immune response is induced that leads to tissue destruction. However, this model might be too simplistic. Literature data suggest that the expression of enzymes crucial for fatty acid oxidation is upregulated in the skin of patients with psoriasis compared with healthy individuals.
  
  
  OBJECTIVE
  To examine the influence of fatty acid oxidation on psoriasis with regard to expression and activity of the key enzyme in fatty acid oxidation, carnitine palmitoyltransferase-1 (CPT-1) and the effect of the CPT-1 inhibitor, Etomoxir.
  
  
  METHODS
  Experiments were performed with homogenates of lesional and healthy skin, fibroblast cultures and a model of human psoriatic skin transplanted on immune-deficient BNX mice.
  
  
  RESULTS
  CPT-1 was highly active in lesional skin. Etomoxir was able to block CPT-1 activity in skin, implying that this antagonist may have the potential to suppress psoriasis when administered topically. In the mouse model, Etomoxir had an antipsoriatic effect that was at least as good as that of betamethasone, as evidenced by reduction of epidermal thickness, keratinocyte proliferation and differentiation.
  
  
  CONCLUSIONS
  We conclude that fatty acid metabolism and in particular CPT-1 may be an excellent target for treatment of psoriasis.
authors.affiliation: Medigene AG, Lochhamerstrasse 11, 82152 Martinsried, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Caspary
authors.forename: G
authors.initials: G
authors.lastname: Elliott
authors.forename: B T
authors.initials: BT
authors.lastname: Navé
authors.forename: P
authors.initials: P
authors.lastname: Verzaal
authors.forename: M
authors.initials: M
authors.lastname: Rohrbach
authors.forename: P K
authors.initials: PK
authors.lastname: Das
authors.forename: L
authors.initials: L
authors.lastname: Nagelkerken
authors.forename: J D
authors.initials: JD
authors.lastname: Nieland
mesh_terms: D000818:Animals; D002334:Carnitine O-Palmitoyltransferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004852:Epoxy Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005227:Fatty Acids / Q000378:metabolism*; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology; D006801:Humans; D051379:Mice; D008812:Mice, Hairless; D010084:Oxidation-Reduction / Q000187:drug effects; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012867:Skin / Q000201:enzymology; D016038:Skin Transplantation; D014183:Transplantation, Heterologous
chemical_list: D004791:Enzyme Inhibitors; D004852:Epoxy Compounds; D005227:Fatty Acids; D002334:Carnitine O-Palmitoyltransferase; C054207:etomoxir